A 52-year-old female...After the laparoscopic exploration and biopsy, immunohistochemistry showed poorly differentiated adenocarcinoma originated from ovarian (cT3NxM1, stage IV, peritoneal and abdominal wall metastasis). The next generation sequence detected ERRFI1 (T187A, exon4) mutation. endostar plus apatinib was administered for 14 cycles and she obtained a PFS of 14 months without long-term adverse events. Importantly, endostar combined with apatinib is worth recommending for maintenance treatment in refractory ovarian cancer.